Diabetes in Kidney Transplantation

Overview

Journal Adv Chronic Kidney Dis

Specialty Nephrology

Date 2022 Apr 3

PMID 35367028

Authors

Maria P Martinez Cantarin

Affiliations

Soon will be listed here.

Abstract

Diabetes mellitus (DM) is one of the most common complications after kidney transplantation and is associated with unfavorable outcomes including death. DM can be present before transplant but post-transplant DM (PTDM) refers to diabetes that is diagnosed after solid organ transplantation. Despite its high prevalence, optimal treatment to prevent complications of PTDM is unknown. Medical therapy of pre-existent DM or PTDM after transplant is challenging because of frequent interactions between antidiabetic and immunosuppressive agents. There is also frequent need for medication dose adjustments due to residual kidney disease and a higher risk of medication side effects in patients treated with immunosuppressive agents. Sodium-glucose cotransporter 2 inhibitors have demonstrated a favorable cardio-renal profile in patients with DM without a transplant and hence hold great promise in this patient population although there is concern about the higher risk of urinary tract infections. The significant gaps in our understanding of the pathophysiology, diagnosis, and management of DM after kidney transplantation need to be urgently addressed.

Citing Articles

Is High-Intensity Interval Training an Option for Post-Kidney Transplant Physical Rehabilitation Programmes? A Scoping Review.

Lovatto V, Sousa B, Maraes V J Multidiscip Healthc. 2025; 18:1231-1239.

PMID: 40041241 PMC: 11878123. DOI: 10.2147/JMDH.S491605.

Diabetes Mellitus as a Risk Factor for Complicated Urinary Tract Infections in Kidney Transplant Recipients.

Krohmals S, de Terwangne C, Devresse A, Goffin E, Darius T, Buemi A J Clin Med. 2025; 14(2).

PMID: 39860624 PMC: 11765767. DOI: 10.3390/jcm14020618.

Influence of gut flora on diabetes management after kidney transplantation.

Chen L, Chen Q, Chao S, Yuan Z, Jia L, Niu Y BMC Nephrol. 2024; 25(1):468.

PMID: 39716100 PMC: 11665093. DOI: 10.1186/s12882-024-03899-y.

The use of metabolomics and machine learning algorithms to predict post-transplant diabetes mellitus in renal transplant patients on Tacrolimus therapy.

Burghelea D, Moisoiu T, Ivan C, Elec A, Munteanu A, Tabrea R Med Pharm Rep. 2024; 97(4):467-476.

PMID: 39502769 PMC: 11534379. DOI: 10.15386/mpr-2780.

Adverse Drug Events after Kidney Transplantation.

Rostaing L, Jouve T, Terrec F, Malvezzi P, Noble J J Pers Med. 2023; 13(12).

PMID: 38138933 PMC: 10744736. DOI: 10.3390/jpm13121706.

References

Jenssen T, Hartmann A . Post-transplant diabetes mellitus in patients with solid organ transplants. Nat Rev Endocrinol. 2019; 15(3):172-188. DOI: 10.1038/s41574-018-0137-7. View

Neal B, Perkovic V, Mahaffey K, de Zeeuw D, Fulcher G, Erondu N . Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377(7):644-657. DOI: 10.1056/NEJMoa1611925. View

Woodle E, First M, Pirsch J, Shihab F, Gaber A, Van Veldhuisen P . A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008; 248(4):564-77. DOI: 10.1097/SLA.0b013e318187d1da. View

Pinelli N, Patel A, Salinitri F . Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series. Diabetes Care. 2013; 36(10):e171-2. PMC: 3781489. DOI: 10.2337/dc13-1066. View

Fridell J, Stratta R . Islet or pancreas after kidney transplantation: Is the whole still greater than some of its parts?. Am J Transplant. 2020; 21(4):1363-1364. DOI: 10.1111/ajt.16232. View

Chowdhury T, Wahba M, Mallik R, Peracha J, Patel D, De P . Association of British Clinical Diabetologists and Renal Association guidelines on the detection and management of diabetes post solid organ transplantation. Diabet Med. 2021; 38(6):e14523. DOI: 10.1111/dme.14523. View

Hecking M, Kainz A, Werzowa J, Haidinger M, Doller D, Tura A . Glucose metabolism after renal transplantation. Diabetes Care. 2013; 36(9):2763-71. PMC: 3747896. DOI: 10.2337/dc12-2441. View

Turk T, Pietruck F, Dolff S, Kribben A, Janssen O, Mann K . Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant. 2006; 6(4):842-6. DOI: 10.1111/j.1600-6143.2006.01250.x. View

Burroughs T, Swindle J, Takemoto S, Lentine K, Machnicki G, Irish W . Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation. 2007; 83(8):1027-34. DOI: 10.1097/01.tp.0000259617.21741.95. View

10.

Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A . Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357(25):2562-75. DOI: 10.1056/NEJMoa067411. View

11.

Eide I, Halden T, Hartmann A, Asberg A, Dahle D, Reisaeter A . Mortality risk in post-transplantation diabetes mellitus based on glucose and HbA1c diagnostic criteria. Transpl Int. 2016; 29(5):568-78. DOI: 10.1111/tri.12757. View

12.

Solomon T, Haus J, Kelly K, Rocco M, Kashyap S, Kirwan J . Improved pancreatic beta-cell function in type 2 diabetic patients after lifestyle-induced weight loss is related to glucose-dependent insulinotropic polypeptide. Diabetes Care. 2010; 33(7):1561-6. PMC: 2890359. DOI: 10.2337/dc09-2021. View

13.

Hecking M, Sharif A, Eller K, Jenssen T . Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics. Transpl Int. 2020; 34(1):27-48. PMC: 7839745. DOI: 10.1111/tri.13783. View

14.

Kim Y, Bailey A, Morris M, Kassam A, Shah S, Diwan T . Kidney transplantation after sleeve gastrectomy in the morbidly obese candidate: results of a 2-year experience. Surg Obes Relat Dis. 2019; 16(1):10-14. DOI: 10.1016/j.soard.2019.09.069. View

15.

Hjelmesaeth J, Flyvbjerg A, Jenssen T, Frystyk J, Ueland T, Hagen M . Hypoadiponectinemia is associated with insulin resistance and glucose intolerance after renal transplantation: impact of immunosuppressive and antihypertensive drug therapy. Clin J Am Soc Nephrol. 2007; 1(3):575-82. DOI: 10.2215/CJN.01471005. View

16.

Baid S, Cosimi A, Farrell M, Schoenfeld D, Feng S, Chung R . Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation. 2001; 72(6):1066-72. DOI: 10.1097/00007890-200109270-00015. View

17.

von During M, Jenssen T, Bollerslev J, Asberg A, Godang K, Eide I . Visceral fat is better related to impaired glucose metabolism than body mass index after kidney transplantation. Transpl Int. 2015; 28(10):1162-71. DOI: 10.1111/tri.12606. View

18.

Gaiffe E, Crepin T, Bamoulid J, Courivaud C, Buchler M, Cassuto E . PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study. Trials. 2019; 20(1):375. PMC: 6588872. DOI: 10.1186/s13063-019-3392-6. View

19.

Johnston O, Rose C, Webster A, Gill J . Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol. 2008; 19(7):1411-8. PMC: 2440303. DOI: 10.1681/ASN.2007111202. View

20.

Sanyal D, Gupta S, Das P . A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting. Indian J Endocrinol Metab. 2013; 17(Suppl 1):S203-5. PMC: 3830305. DOI: 10.4103/2230-8210.119572. View